San Diego, CA 8/21/14; London, England 8/21/14—Illumina has formed collaborative partnerships with AstraZeneca, Janssen Biotech and Sanofi to develop a universal next-generation sequencing (NGS)–based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multigene panel for therapeutic selection. The partnership involves the development of assays to detect and measure multiple variants simultaneously. Illumina is also working with thought leaders to develop standards for NGS-based assays in routine clinical oncology practice and to define the regulatory frameworks. “This partnership has the potential to deliver an unprecedented amount of clinical information from a single test. Illumina’s technology will inform doctors about the molecular make-up of their patients’ tumors, enabling them to match medicines to the drivers of disease,” stated Ruth March, vice president, Personalized Healthcare & Biomarkers at AstraZeneca.